KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) +10.08 (486.96%)
On Thursday, during the Afternoon trading session, shares of KaloBios Pharmaceuticals Inc (NASDAQ:KBIO), higher 494.20% or +10.35 points to $12.23.
Current Trade Update: The firm opened its current trade at $14.00, and as of now, it is trading at $12.37. The total volume traded for the day is 4.55M, as compared to its average daily volume of 608,620.00 shares. The stock is floating in a range of $10.48 - $14.72. The stocks hold the market capitalization of $47.01M.
Short-Term Price Target Update: The mean estimate for the short-term price target for the firm stands at $5.00, according to 1 brokers. The higher price target for KBIO is $5.00, while the lower price target is $5.00. In the past 52-weeks, the company shares have declined -27.4% and marked new low $0.44 on Nov 16, 2015.
KBIO is moving on high volume, trading at a volume of 4.55M, for now, as compared to its average daily volume of 608,620.00 shares. At $12.28, the stock is losing momentum as shares are down from a peak price of $21.05 recorded on Dec 10, 2014. The stock is down -27.4% in this year through last updated price. The stock is having its 200-day moving average of $2.91 and $1.86 as its 50-day moving average. The stock, as of now, is showing weekly upbeat performance of 117.89%, which is maintained at - 2.36% in 1-month period.
The year-to-date (YTD) performance of KBIO stock reflects that it is -85.04% below last year. During the past month, the stock loses - 2.36%, bringing three-month performance to 13.11% and six-month performance to -52.95%.
KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States. The companys product candidates comprise KB004, which is in a Phase II clinical trial for the treatment of myelodysplastic syndrome and myelofibrosis; and KB003 that accomplished Phase II clinical trial to treat chronic myelomonocytic leukemia, an orphan oncology indication. KaloBios Pharmaceuticals, Inc. was founded in 2000 and is headquartered in South San Francisco, California.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.